CN1110147A - Antiallergic composition - Google Patents

Abstract

The present invention provides a composite preparation capable of safely and effectively curing and preventing allergic diseases, such as atopic dermatitis and pollenosis, etc.. Said composite preparation at least includes one kind of bacteria belonging to streptococcus, enterococcus, bifidobacteria, lactobacillus and clostridium or edible culture obtained by cultivating at least one kind of the described bacteria in edible culture medium.

Description

Antiallergic composition

The present invention relates to a kind of treatment and prophylactic agent of allergic disease.

In recent years, for example pollinosis and atopic dermatitis are more and more common, and are considered to a kind of disease of immune system.The cause of disease of this disease and pathogenesis also fail to explain so far, therefore also do not set up any effectively treatment completely or prevention method.At present, has only symptomatic treatment.

The object of the present invention is to provide a kind of anti-allergic drug, it can treat and prevent this disease effectively up hill and dale.

In recent years, the relation between immune system and other organs understands gradually, and more and more Duo people thinks that immune system and other organs are close in the function co-relation.For example known immune system is accepted the effect of cranial nerve system by hormone, under height psychentonia condition, can reduce the activity (Matsuda of natural killer cell (NK), Hirano: " No to Meneki(the Brain and the Iumme) ", TAISHA(METABOLISM), 26, Special No.45-61), (R.Ader et al., " Interactions between the Brain and the Immune System ", Annu.Rev.Pharmacol.Toxicol., 30,561-602(1990)).Further, peyer's patches (Payer patches) is the antigen control immune system tissue via enteral, and intestinal bacterium clump and immune system are considered to closely related.

About allergy (allergies), consider that the relation of it and other organs and living environment has become extremely important.In view of this consideration, the inventor has carried out taking a broad survey in a large number.Found that some cause of disease of allergosis, for example particularly the cause of disease of atopic dermatitis and pollinosis is not very clear, in many cases may with psychiatric system stress be relevant with the intestinal flora imbalance that exists in the digestive tract.Can reach therapeutic purposes by improving these problems.The medicine of also having found to be used to regulate and control traditionally intestinal function is not enough to treat or prevent abnormal reaction, and taking (promptly increased bacterial strain quantity, also increase cell number) intestinal function regulating medicine can heighten the effect of a treatment significantly.These discoveries cause producing the present invention.

Below will describe the present invention in detail.

Inventor's inspected is crossed many patient for allergic reactions for many years.Through Nodje's auricle inspection method (Written by Purdior and translated under the supervision of Yukio Kurosu: " Auricular Acupuncture "-P.Nodje's Theory and clinics, published by The Enterprise K.K.(1985); Written by Nodje andtranslated by Ikubiro Fukuda: " Hand book of Auricular Reflex Points ", published by The Taniguchi shoten K.K(1989); And Written by Ming Hang cho " Obei Jishinho no Riron to Rinsho " (Theories and Clinics of Auricular Acupuncture in Europe and America), published by the Ido No Nihom Sha K.K(1979)).Though having been found that has many serious subjective symptoms that do not have among the patient, their digestive organs intestinal when beginning occurs unusual.Through inquiring, find that also he is in biotonus.The inventor has treated various diseases, and these diseases are all because autonomous imbalance causes that its Therapeutic Method is an auricle electricity therapy, and reaches fabulous curative effect.For allergic disease, electrotherapy and on skin, use the curative effect that use can acquire a certain degree of uniting of anti-infectives, but in many cases, treatment time is long.

Inquiring result to those patients is, many patients are in biotonus, and constipation is perhaps arranged, and the tendency of constipation is perhaps arranged, and perhaps develops into the diarrheal tendency on the contrary, and particularly abdomen rises or aerogenesis, and has unusual intensive stink.Therefore be considered to develop into intestinal flora reaches the intestinal illness to these patients unusually.Known to psychentonia, intestinal flora and digestive tract epithelium are easy to have problems and lack of proper care.

In recent years, usually point out agricultural chemicals, antibiotic, synthetic antimicrobial preparation or the like is used for agricultural, fishery, domestic animal field in large quantities and remains in food.They also become the reason that causes the intestinal flora problem.Therefore in this case, modern viewpoint thinks that intestinal flora is easy to imbalance.The problem that it is believed that imbalance of this intestinal flora and mucous epithelium is to immune system, psychiatric system, and metabolic systems etc. have toxic action, and the result produces variety of issue, for example allergic disease.

According to the present invention, allergy preparations contains at least a, is preferably the multiple gastral representative nonpathogenic bacteria of people that are selected from, and this preparation is taken in visible cell 10 every day ¹¹-10 ¹³Cell.This allergy preparations can improve or keep enteral cell flora, when it and a kind of anti-infective and electrotherapy and time spent, can show the drug effect to allergosis.Adopt the drug dose of regulation and control intestinal function usually, the visible cell counting is less than one of percentage of above-mentioned visible cell counting or still less, their effect is not enough to reach.

Antibacterial

According to the present invention, the bacterial strain that is used for antiallergic action intestinal flora improving agent comprises enterococcus faecalis (Enterococcus faecalis), enterococcus faecalis (Enterococcus faecium), durans kind enterococcus (Enterococcus durans), fowl enterococcus (Enterococcus avium), streptococcus salivarius (Streptococcus salivarius), bargen's streptococcus (Streptococcus bovis), streptococcus equinus (Streptococcus equinus), bacillus acidophilus (Lactobacillus acidophilus), aerobacter aerogenes (Lactobacillus gaseri), Lactobacillus salivarius (Lactobacillus salivarius), yeast milk bacillus (Lactobacillus fermentum), Lactobacillus reuteri, lactobacillus arabinosus (Lactobacillus arabinosus), bifidobacterium breve (Bifidobacterium breve), bifidobacterium longum (Bifidobacterium longum), bifidobacterium adolescentis (Bifidobacterium adolescentis), child's bifidus bacillus (Bifidobacterium infantis), and bifidobacterium bifidum (Bifidobacterium bifidum).

The special bacterial strain that has adopted in the embodiment of the invention is enterococcus faecalis ATCC 19433(Enterococcus faecalis ATCC 19433), enterococcus faecalis ATCC 19434(Enterococcus faecium ATCC 19434), durans kind enterococcus IID 677(Enterococcus durans IID 677), streptococcus salivarius IID 5223(Streptococcus salivarius IID 5223), hirae kind enterococcus ATCC 8043(Enterococcus hirae ATCC 8043), hirae kind enterococcus ATCC 9790(Enterococcus hirae ATCC 9790), bacillus acidophilus ATCC 4356(Lactobacillus acidophilus ATCC 4356), lactobacillus arabinosus ATCC 8014(Lactobacillus arabinosus ATCC 8014), yeast milk bacillus IAM 1148(Lact obacillusfermentum IAM 1148), buttermilk bacillus ATCC 393(Lactobacillus casei ATCC 393), bifidobacterium longum JCM 1217(Bifido bacterium Longum JCM 1217), bifidobacterium bifidum JCM 1254(Bifidobacterium bifidum JCM 1254), lack not tally bacillus JCM 1192(Bifidobacterium breve JCM 1192) and Bacillus butyricus ATCC 6015(Clostridium butyricum ATCC 6015).

Having under the conditions of air, adopting the Rogosa culture medium to cultivate described enterococcus, streptococcus and lactobacillus for 37 ℃.On the other hand, having under the conditions of air, adopting GAM culture medium (product of Nissui Pharmaceutical Co.Ltd) to cultivate enterococcus, streptococcus and lactobacillus bacteria for 37 ℃.The 121 ℃ of sterilizations 15 minutes in autoclave sterilizer of every kind of culture medium.Each bacterial strain is inoculated in the corresponding culture medium, and inoculum concentration is 10 ⁶/ ml.After the strain culturing 15 hours, 12, centrifugal this culture collection cell of 000rpm.The cell of collecting is distributed in 10% the skimmed milk of culture volumetrical 1/20th, carries out lyophilizing subsequently.Every gram lyophilizing bacterial strain of using in following experiment contains about 10 ⁹-10 ¹²Individual cell.

Note that the Rogosa culture medium is: contain in 1 premium on currency:

Trypticase 10g

Yeast extract 5g

Pancreas albumen 3g

K ₂HPO ₄3g

KH ₂PO ₄3g

Ammonium citrate 2g

Tween 80 1g

Glucose 20g

Cysteine 0.2g

Saline solution 5ml

Saline solution is: per 1, contain in the 000ml pure water:

MgSO ₄·7H ₂O 11.5g

FeSO ₄·7H ₂O 0.68g

MnSO ₄·ZH ₂O 2.4g

Patient in the following experiment had accepted electrotherapy and had also used a kind of antiinflammatory ointment (Shiunko) simultaneously.Shiunko is a kind of traditional Japanese ointment, adopt the heating Oleum sesami, Cera Flava, Adeps Sus domestica and A.acutiloba's root (Japanese arigeliea root), add Radix Arnebiae (Radix Lithospermi) (lithospermun root) again, boil and boil one or the mixture that obtains of secondary, sieve then, get described oily composition and make this ointment, by using the curative effect that curative effect that the following antiallergic composition of the present invention reaches more only uses electrotherapy and antiinflammatory ointment (Shiunko) to reach, and more commercially available intestinal function regulation and control antibacterial, the product of Nakamo to Pharmaceutical CO.ltd) and " Biothree " (trade mark: the product of Toa Pharmaceutical Co.Ltd) with the curative effect behind the described oral dose, these medicines are " Lebenin " (trade mark:.

Employed strain name and visible cell calculate and see Table 1 in the experimental example.

Experimental example 1

Above-mentioned weight such as bacterial strain freeze drying cell are mixed, and get a blended freeze drying cell powder.With pack into the gelatine capsule of 500mg size of freeze-dried mixed cell powder, day clothes three times, each one.

Experimental example 2

Mixed freeze drying cell powder added in 1 liter the commercially available milk of freezing mistake.The mixture that obtains is placed in the couveuse, and 40 ℃ kept 8-12 hour.Milk becomes semisolid slightly.Cold preservation, about 500 milliliters of day drink.When drinking, can be with sugar, aspartame (As partame), oligosaccharide or other sweeting agents, fruit jam, fruit and/or its analog add described semisolid milk.

Experimental example 3

With hirae kind enterococcus ATCC 9790(Enterococcus hirae ATCC 9790) pack into the gelatine capsule of 500mg size of freeze drying cell, day clothes three times, each one.

Experimental example 4

With bacillus acidophilus ATCC 4356(Lactob acillus acidophilus ATCC 4356) pack into the gelatine capsule of 500mg size of freeze drying cell, day clothes three times, each one.

Experimental example 5

With bifidobacterium longum JCM 1217(Bifidob acterium longum JCM 1217) pack into the gelatine capsule of 500mg size of freeze drying cell, day clothes three times, each one.

Experimental example 6

Each experiment was carried out 3 months.The preservation in the bottle of 4 ℃ or lower temperature lower seal of freeze drying cell or capsule that freeze drying cell is housed.

It the results are summarized in the table 2.As seen the advantage of the present invention's antiallergic composition fully aware of.Also having more efficiently than single use with discovery of multiple bacterial strain acts on.

Advantage of the present invention, as mentioned above, the present invention's anti-allergic drug has positive effect to atopic dermatitis etc.

Employed strain name and visible cell calculate in table 1 experimental example

The bacteria name plate count

(cell/g)

Enterococcus faecalis (Enterococcus

faecalis) ATCC 19433 10 ^11.6

Enterococcus faecalis (Enterococcus

faecium) ATCC 19434 10 ^11.9

Durans kind enterococcus (Enterococcus

durans)IID 667 10 ^11.7

Hirae kind enterococcus (Enterococcus

hirae)ATCC 8043 10 ^11.6

Hirae kind enterococcus (Enterococcus

hirae)ATCC 9790 10 ^11.7

Streptococcus salivarius (Streptococcus

salivarius)IID 5223 10 ¹²

Bacillus acidophilus (Lactobacillus

acidophilus)ATCC 4356 10 ^10.7

(continuous table 1)

The bacteria name plate count

(cell/g)

Lactobacillus arabinosus (Lactobac-

illus arabinosus)ATCC 8014 10 ⁹

Yeast milk bacillus (Lactobacillus

fermentum)IAM 1148 10 ^9.7

Buttermilk bacillus (Lactobacillus

casei)ATCC 393 10 ^10.3

Bifidobacterium adolescentis (Bifidobac-

terium adolesentis)ATCC 15705 10 ⁹

Bifidobacterium longum (Bifidob-

acterium longum)JCM 1217 10 ^9.3

Bifidobacterium bifidum (Bifidoba-

cterium bifidum)JCM 1254 10 ^9.7

Bifidobacterium breve (Bifidobact-

erium breve)JCM 1192 10 ⁹

Bacillus butyricus (Clostridum

butyricum)ATCC 6015 10 ^10.3

Table 2

Effect for the atopic dermatitis patient

(each numeral case load in the table)

A group: electrotherapy+use Shiunko

The B group: electrotherapy+use Shiunko+ takes commercially available intestinal function regulation and control visible cell medicine.

The C group: electrotherapy+use Shiunko+ takes commercially available intestinal function regulation and control visible cell medicine (Biothree)

D group: experimental example 1 F group: experimental example 3

E group: experimental example 2 G group: experimental example 4

H group: experimental example 5

Significant effective:

Skin does not have keratinization, and the erythema color transfers to normally, or approaches normally, the basic disappearance of scratching where it itches.Or skin infection area decreases about 50% or more.

Effectively:

Keratinization alleviates, and the erythema color obviously shoals.Or skin infection area decreases about 20% or more.

Invalid:

In fact there is not improvement, even or improve just very limited yet.

Claims (2)

1, a kind of allergy preparations comprises at least a Streptococcus that belongs to, Enterococcus, Bifidobacterium, the visible cell as effective ingredient of Lactobacillus and Clostridium antibacterial.

2, a kind of allergy preparations comprises and a kind ofly in edible culture medium at least a visible cell as claimed in claim 1 is cultivated the culture that obtains as its effective ingredient.